Comparative Pharmacology
Head-to-head clinical analysis: LUZU versus PENLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUZU versus PENLAC.
LUZU vs PENLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Luliconazole inhibits fungal lanosterol 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Ciclopirox, a hydroxypyridone antifungal, inhibits the uptake of essential elements and disrupts fungal cell membrane integrity by chelating polyvalent cations (Fe3+, Al3+). It also inhibits fungal enzymes involved in energy production and detoxification processes.
Apply a thin layer of luliconazole 1% cream to the affected skin once daily for 2 weeks (tinea pedis), 1 week (tinea cruris, tinea corporis).
Apply a thin layer to affected nails once daily, preferably at bedtime or 8 hours before washing. Use the provided applicator to apply to the entire nail plate and under the nail tip. Treatment duration is up to 48 weeks.
None Documented
None Documented
The terminal elimination half-life is approximately 140 hours (range 130-177 hours); this long half-life supports once-daily dosing and provides sustained drug concentrations in the skin following topical application.
Terminal elimination half-life is 17–21 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe renal failure)
Luliconazole is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 1% of the dose; fecal excretion accounts for approximately 78-82% of the administered dose as metabolites; biliary excretion is a minor route.
Primarily excreted renally as unchanged drug; approximately 90% of absorbed dose recovered in urine within 24 hours; minimal biliary/fecal elimination (<5%)
Category C
Category C
Topical Antifungal
Topical Antifungal